Beyond Weight Loss: What the Latest GLP-1 Results Mean for Patients
In the past two weeks, three results have shown that the medicines most people know as weight-loss drugs are being tested far beyond weight - and one large failure has shown where the limits are. If you take one of these medicines, or are thinking about it, none of this changes your treatment today. But it is worth understanding what is actually happening, because the headlines rarely explain it well.
The most striking result came on July 28. Altimmune reported that pemvidutide, a drug in the same family as Wegovy and Zepbound, reduced heavy drinking days in people with moderate to severe alcohol use disorder. In a trial of about 100 patients over 24 weeks, nearly two thirds dropped two levels on the World Health Organization's risk-drinking scale, and participants also lost about 9 percent of their body weight compared with placebo. Many people taking GLP-1 medicines have said for years that their desire to drink faded; this is among the clearest evidence so far that the effect is real and measurable.
Two important cautions. First, this was a Phase 2 trial - a middle stage. It has to be repeated in a much larger Phase 3 study before any regulator will consider approving the drug for this use, and that takes years. Second, no GLP-1 medicine is approved today for alcohol use disorder anywhere. If you are struggling with alcohol, the treatments that exist now - counselling, support groups, and the approved medicines your doctor can prescribe - are what is available, and they help many people.
You may also have read that Eli Lilly is giving some patients early access to retatrutide, an obesity drug that is not yet approved. This is called expanded or compassionate access, and it is narrower than it sounds. It is meant for people with a serious condition who cannot join a clinical trial and have no suitable approved alternative. A doctor has to apply on the patient's behalf, the company has to agree, and the regulator has to allow it. It is not a way to get a new drug early because you would prefer it.
The other side of the same fortnight is a reminder worth keeping. On July 31, Novo Nordisk's ziltivekimab - an anti-inflammatory heart drug, not a GLP-1 - failed its large ZEUS trial: it did not reduce serious cardiovascular events compared with placebo. Days later, Amgen stopped early development of one of its own obesity candidates. Most experimental medicines fail, including ones that looked promising. That is normal, and it is exactly why approval requires large trials rather than early enthusiasm.
What should you do with all this? If you are on a GLP-1 medicine, keep taking it as prescribed; nothing here changes that. If a new use interests you - alcohol, liver disease, heart health - ask your doctor whether a clinical trial near you is recruiting, which is the legitimate way to access an unapproved treatment. And treat any headline promising a breakthrough with patience: the gap between a good Phase 2 result and a medicine you can collect at a pharmacy is usually several years. This is general information, not medical advice.